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Objectives The aim of this study was to compare the survival of patients with hypertrophic cardiomyopathy (HCM) and rest-
ing left ventricular outflow tract (LVOT) obstruction managed with an invasive versus a conservative strategy.
Background In patients with resting obstructive HCM, clinical benefit can be achieved after invasive septal reduction therapy.
However, it remains controversial whether invasive treatment improves long-term survival.
Methods We studied a consecutive cohort of 649 patients with resting obstructive HCM. Total and HCM-related mortality
were compared in 246 patients who were conservatively managed with 403 patients who were invasively man-
aged by surgical myectomy, septal ethanol ablation, or dual-chamber pacing.
Results Multivariable analyses (with invasive therapy treated as a time-dependent covariate) showed that an invasive
intervention was a significant determinant of overall mortality (hazard ratio: 0.6, 95% confidence interval: 0.4 to
0.97, p  0.04). Overall survival rates were greater in the invasive (99.2% 1-year, 95.7% 5-year, and 87.8%
10-year survival) than in the conservative (97.3% 1-year, 91.1% 5-year, and 75.8% 10-year survival, p  0.008)
cohort. However, invasive therapy was not found to be a significant independent predictor of HCM-related mortal-
ity (hazard ratio: 0.7, 95% confidence interval: 0.4 to 1.3, p  0.3). The HCM-related survival was 99.5% (1 year),
96.3% (5 years), and 90.2% (10 years) in the invasive cohort, and 97.8% (1 year), 94.6% (5 years), and 86.9%
(10 years) in the conservative cohort (p  0.3).
Conclusions Patients treated invasively have an overall survival advantage compared with conservatively treated patients,
with the latter group more likely to die from noncardiac causes. The HCM-related mortality is similar, regardless
of a conservative versus invasive strategy. (J Am Coll Cardiol 2011;58:2313–21) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.040Hypertrophic cardiomyopathy (HCM) is a genetic dis-
order of the cardiac sarcomere (1–3). Asymmetric septal
hypertrophy is the most common manifestation of this
condition, and a significant number of patients have
associated left ventricular outflow tract (LVOT) obstruc-
tion (4 – 6). The long-term prognosis of patients with
HCM and LVOT obstruction in the contemporary era
remains unclear. Patients with New York Heart Associ-
ation (NYHA) functional class III/IV symptoms are
generally started on pharmacotherapy (5). In patients
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accepted August 15, 2011.who remain symptomatic or who become intolerant of
medications, an invasive intervention is warranted. Inva-
sive therapeutic options include surgical myectomy, dual-
chamber (DDD) permanent pacing, or septal ethanol
ablation (SEA) (5). Although significant hemodynamic
and clinical benefit can be achieved after invasive relief of
the LVOT obstruction, it remains controversial whether
abolition of the LVOT gradient actually improves long-
term survival (7).
One large observational study has demonstrated that
patients with HCM and LVOT obstruction have a worse
long-term prognosis when compared with patients with-
out obstruction (6). However, there are no randomized
trials of medical versus invasive therapy, and the majority
of retrospective cohort studies were done before the
modern era. Another study suggested that patients with
LVOT obstruction managed with surgical myectomy
g
m
L
r
v
s
a
g
n
p
L
M
a
p
o
S
m
c
a
m
p
m
c
t
C
g
w
t
c
f
m
t
v
P
t
r
m
t
t
f
L
w
b
o
I
a
D
1
i
F
p
t
c
D
o
p
3
o
p
t
u
o
c
w
E
B
S
a
t
2314 Ball et al. JACC Vol. 58, No. 22, 2011
Survival in Patients With Obstructive HCM November 22, 2011:2313–21have better survival than conser-
vatively treated patients (8). How-
ever, in this study, the medi-
cally and surgically managed
patients were treated at differ-
ent institutions, raising issues
of referral bias. Therefore, we
sought to compare the survival
of patients with obstructive
HCM who were treated con-
servatively with those treated
invasively at a single tertiary
care referral center. We also
evaluated the factors predicting
long-term survival in patients
with resting obstructive HCM.
Methods
Study population and data collection. This study in-
cluded consecutive adult patients (18 years of age at initial
presentation to the Toronto General Hospital [TGH]) with
resting obstructive HCM who were referred to our institu-
tion between 1986 and 2007. Some of these patients were
included in previous publications from our institution
(9,10), but clinical and echocardiographic follow-up were
updated from the time of completion of these studies. The
diagnosis of HCM was established by the presence of
asymmetric septal hypertrophy (septum 13 mm), in the
absence of another condition that could account for the
degree of hypertrophy observed (5). Echocardiographic data
were obtained, as described previously (11), and LVOT
gradients were determined by continuous wave Doppler
assessment (11,12). Only patients with resting LVOT
obstruction, defined as a resting gradient of 30 mm Hg,
were included. The following conditions excluded patients
from this study: other congenital syndromes (e.g.,
Noonan’s), a fibrous subaortic membrane, significant aortic
stenosis (defined as an aortic valve area 1.2 cm2 or peak
radient 30 mm Hg across aortic valve), HCM with
idventricular obstruction, HCM with pure provocable
VOT obstruction (i.e., LVOT gradient 30 mm Hg at
est but 30 mm Hg only after provocation), significant
alvular lesions (other than mitral regurgitation due to
ystolic anterior motion), and significant epicardial coronary
rtery disease (coronary stenosis [70%] on coronary an-
iography, previous bypass surgery, or percutaneous coro-
ary intervention). Finally, we excluded patients who had
reviously undergone invasive procedures to treat their
VOT obstruction at other institutions.
anagement of patients with obstructive HCM: conservative
nd invasive management. Over the course of the study
eriod, the approach to the management of patients with
bstructive HCM adhered to the following principles.
ymptomatic patients were typically initially treated with
Abbreviations
and Acronyms
CI  confidence interval
DDD  dual-chamber
HCM  hypertrophic
cardiomyopathy
LVOT  left ventricular
outflow tract
NYHA  New York Heart
Association
SCD  sudden cardiac
death
SEA  septal ethanol
ablation
TGH  Toronto General
Hospitaledications (beta blockers, disopyramide, and/or calciumhannel blockers). Patients were referred for invasive man-
gement in the presence of unacceptable symptoms despite
aximally tolerated medical therapy. The choice of invasive
rocedure (myectomy, SEA, or DDD pacing) was deter-
ined by the managing physician, taking into account the
linical profile of the patient, presence of comorbid condi-
ions, and his/her individual preferences.
lassification of patients. Patients were classified into 2
roups: 1) the conservative group, comprising those patients
ho received only medications (or no therapy) throughout
he entire follow-up period; and 2) the invasive group,
omprising patients who underwent (at any point during the
ollow-up period) any of the following procedures for
anagement of their LVOT obstruction: 1) surgical myec-
omy; 2) SEA; or 3) DDD pacing. Patients in the conser-
ative group were subclassified according to clinical status.
atients in the invasive group might have received medical
herapy at the time of presentation but were subsequently
eferred for an invasive procedure. If patients underwent
ore than 1 procedure to treat their LVOT obstruction,
hey remain categorized according to the initial invasive
reatment. Although DDD pacing has largely fallen out of
avor as a treatment strategy in patients with HCM and
VOT obstruction (5), we included patients who under-
ent DDD pacing in the invasively managed cohort,
ecause pacing was considered a reasonable therapeutic
ption for much of the 1990s.
nvasive procedures. Surgical myectomy was performed,
s previously described, throughout the study period (10).
ual-chamber pacing has been offered at TGH since the
990s (13). Septal ethanol ablation has been available at our
nstitution since 1998 (9).
ollow-up and definition of outcomes. The status of
atients was determined by cross-sectional follow-up, with
he most recent evaluation available in the last 2 years. We
lassified deaths as HCM-related or noncardiovascular.
eaths were considered to be HCM-related in the presence
f 1 of the following: 1) death within 30 days of an invasive
rocedure; 2) sudden cardiac (nontraumatic) death (SCD);
) heart failure-related death; or 4) stroke-related death. For
ur survival analyses, resuscitated cardiac arrest and appro-
riate implantable cardioverter-defibrillator discharges were
reated as HCM-related and sudden deaths. Patients who
nderwent cardiac transplantation were censored at the time
f transplantation. In instances when the cause of death
ould not be determined, an HCM-related cause of death
as ascribed.
thics. This study was approved by the Research Ethics
oard of our institution.
tatistical analysis. Continuous and categorical data were
nalyzed with t tests, Wilcoxon rank-sum tests, chi-square
ests, or McNemar’s test, where appropriate.
MULTIVARIABLE MODELS. The primary survival analyses
were performed with the Cox proportional hazards model
(14). Univariate and multivariable models were developed to
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November 22, 2011:2313–21 Survival in Patients With Obstructive HCMassess the independent determinants of overall and HCM-
related mortality. All patients had the same start point in
these models, defined at the date of the first visit at our
HCM Clinic. Importantly, to evaluate the impact of inva-
sive intervention on mortality, we treated the invasive
intervention as a time-dependent covariate in the models for
overall and HCM-related mortality. Therefore, in the
invasively treated patients, the period before invasive treat-
ment was treated in the model as survival due to noninvasive
therapy, whereas the period from the date of the invasive
intervention to the date of last follow-up was treated as
survival due to invasive therapy. In the conservative group,
the entire period of observation was thus treated as survival
due to noninvasive therapy.
KAPLAN-MEIER METHOD. Kaplan-Meier survival curves were
onstructed to graphically represent overall and HCM-related
urvival in the conservative and invasive groups (15). By
ecessity, the periods of observation used in this analysis were
ifferent for these 2 groups. In the conservative group, the
eriod of observation began at the date of the initial visit at
GH. However, in the invasive group, the period of observa-
ion began from the date of the invasive intervention. This
ethod of representing the different observation times has
een previously employed in this patient population (8).
ifferences in survival were compared with the log-rank test,
nd a p value0.05 was considered statistically significant. All
tatistical analyses were performed with SAS (versions 9.1 and
.2, Cary, North Carolina). In addition, we used NCSS/PASS
Baseline CharacteristicsTable 1 Baseline Characteristics
Baseline Study Population
Conservative Gr
(n  246)
Age, yrs 57 16
Male 122 (50%)
Clinical status
Shortness of breath 181 (73.6%)
Chest pain 133 (54.1%)
Syncope 33 (13.4%)
NYHA functional class I or II 164 (66.7%)
NYHA functional class III or IV 82 (33.3%)
Drug therapy
Beta-blockers 141 (57.3%)
Disopyramide 60 (24.4%)
Calcium-channel blockers 26 (10.6%)
Comorbidities
Diabetes 20 (8.1%)
Renal/hepatic dysfunction 10 (4.1%)
GI tract disorder 12 (4.9%)
Malignancy 6 (2.4%)
Prior stroke 4 (1.6%)
Any above comorbidity 45 (18.3%)
Echocardiography
Septal thickness, mm 19.9 4.6
Left atrial diameter, mm 44.4 7.3
Resting LVOT gradient, mm Hg 63.1 30.8Values are mean  SD or n (%).
GI  gastrointestinal; LVOT  left ventricular outflow tract; NYHA  New Yoftware (Kaysville, Utah) to calculate the statistical power of
omparing survival in the invasive treatment groups.
esults
aseline characteristics. From 1986 to 2007, 649 patients
ith HCM and resting LVOT obstruction were referred to
he TGH HCM Clinic (Table 1). At the baseline clinical
ssessment, invasively managed patients were 10 years
ounger (47  15 years vs. 57  16 years, p  0.0001),
ore symptomatic (60% NYHA functional class III/IV vs.
3%, p 0.0001), had a thicker septum (22 5 mm vs. 20 
mm, p  0.0001), and had a slightly higher resting
radient (70 33 mm Hg vs. 63 31 mm Hg, p 0.002),
ompared with the conservatively managed patients. Pa-
ients in the conservative group had a higher burden of
ajor comorbidities (diabetes, malignancy, renal or liver
ysfunction, gastrointestinal tract disorder, previous stroke)
han patients in the invasive group (18.3% vs. 8.4%, respec-
ively, p  0.0002) (Table 1).
ationale for conservative therapy. The majority of pa-
ients (81%) in the conservative group were continued on
edical therapy, because they reported mild (NYHA func-
ional class I/II) symptoms during follow-up. The remain-
er of the patients were NYHA functional class III/IV but
ad not undergone an intervention for the following rea-
ons: 1) 13 patients were still undergoing a trial of medica-
ions at the time of the last visit; 2) 10 patients were
ccepted for an invasive procedure but were still awaiting
Invasive Group
(n  403)
Total
(n  649) p Value
47 15 51 16 0.0001
243 (60%) 365 (56%) 0.0006
347 (86.1%) 528 (81.4%) 0.0001
289 (71.7%) 422 (65.0%) 0.0001
106 (26.3%) 139 (21.4%) 0.0001
161 (40.0%) 325 (50.1%) 0.0001
242 (60.0%) 324 (49.9%) 0.0001
241 (59.8%) 382 (58.9%) NS
187 (46.4%) 247 (38.1%) 0.0001
48 (11.9%) 74 (11.4%) NS
12 (3.0%) 32 (4.9%) 0.003
5 (1.2%) 15 (2.3%) 0.03
5 (1.2%) 17 (2.6%) 0.009
10 (2.5%) 16 (2.5%) NS
4 (1.0%) 8 (1.2%) NS
34 (8.4%) 79 (12.2%) 0.0002
21.8 5.3 21.1 5.2 0.0001
45.9 7.5 45.4 7.4 0.016
70.4 33.0 67.6 32.4 0.002oupork Heart Association.
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Survival in Patients With Obstructive HCM November 22, 2011:2313–21the intervention at the time of the last assessment; 3) 13
patients were advised but refused to undergo an invasive
procedure; and 4) 10 patients were not offered an interven-
tion because of serious comorbidities.
Invasive procedures. Over this 21-year period, 246 pa-
tients were managed conservatively, whereas 403 patients
underwent an invasive procedure. There was 1 death in a
patient while awaiting an invasive intervention (SEA)—this
patient was classified in the conservative group, because he
had not undergone intervention before his death. In the
invasively managed group, the mean duration of conserva-
tive therapy before the invasive intervention was 1.6  2.6
ears (range, 1 day to 15 years), totaling 652 patient-years of
onservative management. At the time the decision was
ade to proceed with an intervention, the majority of
atients had NYHA functional class III/IV symptoms.
here were 107 patients with NYHA functional class I/II
ymptoms, for whom invasive treatment was felt to be
ustified: 1) 87 patients had unacceptable symptoms or
ntolerable side effects from medications; 2) 16 patients
eveloped symptomatic atrial fibrillation; and 3) 4 patients
ad a previous cardiac arrest in the presence of significant
VOT obstruction. Surgical myectomy was performed in
87 patients, SEA was performed in 85 patients, and DDD
acemaker implantation was performed in 31 patients.
eri-procedural complications. The overall rate of serious
eri-procedural complications was very low for all invasive
rocedures. In the myectomy group, there was 1 death
0.3%), 4 ventricular septal defects (1.6%), 3 strokes (1.2%),
nd 18 patients (6.2%) requiring a permanent pacemaker in
he early post-operative period. There were no peri-
rocedural deaths in the SEA group. However, unwanted
Clinical and Echocardiographic Data at Last FolTable 2 Clinical and Echocardiographic Dat
Conservative
Group
Clinical status
NYHA functional class I/II
Baseline 67%
Last follow-up 86%*
Medications
Beta-blockers
Baseline 57%
Last follow-up 87%
Disopyramide
Baseline 24%
Last follow-up 62%
Calcium-channel blockers
Baseline 11%
Last follow-up 12%
Resting LVOT gradient, mm Hg
Baseline 63 31
Last follow-up 44 35†
*p NS between conservative and invasive groups at the time of last f
of last follow-up.
Abbreviations as in Table 1.myocardial infarction (distant from the targeted septum)
occurred in 2 patients (2.1%), and there was 1 coronary
dissection (necessitating urgent bypass surgery and myec-
tomy). A permanent pacemaker was required in 22 patients
(25.9%) after SEA. In patients managed with DDD pacing,
there were no serious peri-procedural complications.
Long-term clinical follow-up. The mean follow-up dura-
tion was 7.2  5.5 years. Forty-two patients (6.5%) were
lost to follow-up. The majority of these patients (71%) lived
outside our metropolitan area and follow-up could not be
obtained. Twenty-four (57%) of the patients whose recent
clinical status could not be ascertained had 3 years of
follow-up. Improvements in the clinical and hemodynamic
status are summarized in Table 2. The 2 main reasons for
continued pharmacotherapy in the patients in the invasive
group were the following: 1) 101 patients were being
managed for atrial/supraventricular arrhythmias; and 2) 95
patients had ongoing LVOT obstruction (resting LVOT
gradient 30 mm Hg in 16 patients, provocable LVOT
gradient 30 mm Hg in 79 patients). Patients in the
invasive cohort who remained on medications were signif-
icantly more likely to have: 1) undergone DDD pacing or
SEA instead of myectomy; 2) been older at the time of
invasive intervention; and 3) had a higher provocable
LVOT gradient during follow-up (28.5  25.3 mm Hg vs.
6.5  14.1 mm Hg, p  0.0001), compared with patients
ho were not receiving cardiac medications at the time of
heir last follow-up. A minority of patients (2.7%) in the
nvasive group required a second intervention to treat
ersistent symptomatic LVOT obstruction after their index
rocedure: 7 of 31 (22.6%) of the DDD pacing patients
equired subsequent SEA (n 3) or myectomy (n 4), and
p Visitast Follow-Up Visit
p Value
(Baseline vs.
ast Follow-Up)
Invasive
Group
p Value
(Baseline vs.
Last Follow-Up)
0.0001 40% 0.0001
87%*
0.003 60% 0.01
51%
0.001 46% 0.0001
12%
NS 12% NS
12%
0.0001 70 33 0.0001
11 13†
p. †p 0.0001 between conservative and invasive groups at the timelow-Ua at L
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November 22, 2011:2313–21 Survival in Patients With Obstructive HCM4 of 85 (4.7%) of the SEA patients required subsequent
myectomy at 1.7 0.9 years after the SEA procedure. None
of the patients in the myectomy group required a second
intervention to treat ongoing obstruction.
Overall and HCM-related survival. There were a total of
81 (12.5%) deaths (including resuscitated cardiac arrests and
appropriate implantable cardioverter-defibrillator dis-
charges) in the entire study cohort (Table 3). Three patients,
all in the invasive group, underwent cardiac transplantation
(after myectomy) and were censored at the time of these
events. Invasive therapy (treated as a time-dependent cova-
riate) was a significant determinant of overall mortality
(hazard ratio [HR]: 0.6, 95% confidence interval [CI]: 0.4
to 0.97, p  0.04). The other significant predictors of
overall mortality on multivariable analysis were the follow-
ing (Table 4): 1) age 50 years (HR: 2.6, 95% CI: 1.6 to
.3, p  0.0001); 2) female sex (HR: 2.0, 95% CI: 1.3 to
.2, p  0.002); and 3) septal thickness 20 mm (median
thickness) (HR: 1.7, 95% CI: 1.02 to 2.7, p  0.04). The
presence of a resting LVOT gradient 64 mm Hg (median
LVOT gradient) was of borderline statistical significance
(HR: 1.6, 95% CI: 0.98 to 2.5, p  0.06). In terms of
HCM-related mortality, invasive therapy (as a time-
dependent covariate) was not found to be a significant
independent predictor (HR: 0.7, 95% CI: 0.4 to 1.3, p 
0.3). The HCM-related mortality was predicted by 4
Overall Mortality and Equivalents of MortalityTable 3 Overall Mortality and Equivalents of Mortality
Conservative
Group
(n  246)
Invasive
Group
(n  403)
Total
(n  649)
Mortality
HCM-related mortality 19 (7.7) 28 (6.9) 47 (7.2)
Sudden cardiac death 8 (3.3) 7 (1.7) 15 (2.3)
Non–HCM-related death 16 (6.5) 8 (2.0) 24 (3.7)
Overall mortality 35 (14.2) 36 (8.9) 71 (10.9)
Equivalents of mortality
Resuscitated cardiac arrest 2 (0.8) 4 (1.0) 6 (0.9)
Appropriate ICD discharge* 1 (0.4) 3 (0.7) 4 (0.6)
Total mortality and
equivalents of mortality
38 (15.4) 43 (10.7) 81 (12.5)
Values are n (%). *A total of 55 patients (8.5% of the study cohort) received an implantable
cardioverter-defibrillator (ICD) (for primary prevention [on the basis of presence of risk factors for
sudden death] or secondary prevention).
HCM  hypertrophic cardiomyopathy.
Clinical and Echocardiographic Predictors of OvTable 4 Clinical and Echocardiographic Pred
Variable*
Overall Surviva
HR (95% CI)
Age 50 yrs 2.6 (1.6–4.3)
Female 2.0 (1.3–3.2)
Septal thickness 20 mm 1.7 (1.02–2.7)
Resting LVOT gradient 64 mm Hg 1.6 (0.98–2.5)
Invasive treatment† 0.6 (0.4–0.97)
*The group of patients without the indicated feature represents the re
covariate.
CI  confidence interval; HR  hazard ratio.independent variables: 1) age 50 years (HR: 2.0, 95% CI:
1.1 to 3.4, p  0.01); 2) female sex (HR: 2.1, 95% CI: 1.2
to 3.6, p  0.006); 3) septal thickness 20 mm (HR: 2.0,
95% CI: 1.1 to 3.6, p  0.02); and 4) resting LVOT
radient 64 mm Hg (HR: 1.7, 95% CI: 1.0 to 3.0, p 
.0496). Kaplan-Meier estimates of overall and HCM-
elated survival are shown in Figures 1 and 2. Overall
survival rates were greater in the invasive (99.2  0.5% at 1
year, 95.7  1.2% at 5 years, and 87.8  2.4% at 10 years)
than in the conservative cohort (97.3  1.1% at 1 year, 91.1 
2.2% at 5 years, and 75.8  4.2% at 10 years, p  0.008).
However, there was no significant difference in HCM-
related survival between the invasive (99.5  0.4% at 1 year,
96.3  1.2% at 5 years, and 90.2  2.3% at 10 years) and
he conservative (97.8  1.0% at 1 year, 94.6  1.7% at 5
years, and 86.9  3.3% at 10 years, p  0.33) groups.
CLASSIFICATION OF DEATHS. A larger proportion of pa-
tients in the conservative group, which had a higher prev-
alence of coexistent medical conditions, died from noncar-
diac causes (6.5% vs. 2.0%, p  0.003) (Table 3). The
majority of the noncardiac deaths were due to malignancy
(n  7), severe intrinsic lung disease (n  5), or gastroin-
testinal/hepatic disorders (n  3). Patients who died from
noncardiac causes were much older (71  13 years vs. 62 
17 years, p  0.03) at the time of death than patients who
died of HCM-related causes.
INVASIVE TREATMENT GROUP: COMPARISON OF SURVIVAL
AMONG THE DIFFERENT INVASIVE THERAPIES. Within the
ohort of invasively managed patients, there was a signifi-
ant difference in total and HCM-related survival, depend-
ng on the invasive treatment selected. On multivariable
nalysis (with the time-varying covariate), there was no
ignificant difference in overall survival between patients
ho underwent myectomy or SEA (p 0.3). Overall 1-year
nd 5-year survival were 99.7  0.4% and 97.0  1.2%,
espectively, in the myectomy group and 98.8  1.2% and
1.4  4.5%, respectively, in the SEA group. The subset of
atients who underwent DDD pacing had significantly
orsened overall survival, with multivariable analysis (with
he time-varying covariate) showing increased total mortal-
ty (HR: 2.6, 95% CI: 1.2 to 5.6, p  0.02). The corre-
ponding 1- and 5-year overall survival in the DDD group
Mortalitys of Overall Mortality
p Value
HCM-Related Survival
HR (95% CI) p Value
0.0001 2.0 (1.1–3.4) 0.01
0.002 2.1 (1.2–3.6) 0.006
0.04 2.0 (1.1–3.6) 0.02
0.06 1.7 (1.0–3.0) 0.0496
0.04 — 0.30 (NS)
category for the calculation of risk. †Variable treated as time-varyingerallictor
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Survival in Patients With Obstructive HCM November 22, 2011:2313–21was 96.4  3.5% and 81.0  8.8%, respectively. In terms of
CM-related survival, multivariable analysis (with the
ime-varying covariate) also revealed no significant differ-
nce in patients who underwent myectomy versus SEA (p
0.6). The HCM-related survival was worse in the pacing
group (HR: 2.5, 95% CI: 1.01 to 6.03, p  0.047),
compared with the other 2 interventions, myectomy and
SEA, although this result was of borderline statistical
significance. The HCM-related survival at 1 and 5 years was
99.7  0.4% and 97.0  1.2%, respectively, in the myec-
tomy group; 98.8  1.2% and 92.8  4.3%, respectively, in
the SEA group (p  0.3 for myectomy vs. SEA); and 95.2 
4.5% and 90.5  4.3%, respectively, in the pacing group.
However, the analysis comparing the SEA and myectomy
groups was insufficiently powered (80% power) to detect a
statistically significant difference.
COMPARISON OF SURVIVAL BETWEEN CONSERVATIVE
THERAPY AND DIFFERENT TYPES OF INVASIVE TREATMENT.
We performed additional multivariable analyses of conser-
vative versus invasive treatment, given the aforementioned
worsened survival in the DDD pacing group, and specifi-
cally excluded the pacing cohort from the invasive group.
These results showed that an invasive intervention was still
associated with significantly improved overall survival (HR:
0.5, 95% CI: 0.3 to 0.8, p  0.005). The strength of this
ssociation with total survival was better when the pacing
roup was excluded rather than when it was included in the
nvasive cohort. However, there was still no difference in
CM-related survival between the conservative and invasive
myectomy and SEA patients only, excluding pacing group)
ohorts on multivariable analysis (p  0.13). Furthermore,
when we restricted our analysis to the conservative group
versus the myectomy group (specifically excluding patients
who underwent SEA or DDD pacing), there was a distinct
Figure 1 Comparison of Overall Survival in
Patients With Resting Obstructive HCM
Kaplan-Meier plots of overall survival in patients with hypertrophic cardiomyopa-
thy (HCM) and resting left ventricular outflow tract obstruction managed with
either invasive (INV) or conservative (CONS) therapy (p  0.008).survival advantage in the myectomy group in terms ofall-cause mortality (HR: 0.5, 95% CI: 0.3 to 0.8, p 
.004). Nonetheless, there was no significant difference in
CM-related survival between the conservative and the
yectomy groups (p  0.16).
onservative management of obstructive HCM. Multi-
variable analyses (with invasive intervention as a time-
varying covariate) demonstrated that there was no signifi-
cant difference in overall or HCM-related survival between
the conservatively managed class I/II patients and the
patients in the invasive group (p  0.3 and p  0.7,
espectively). Conservatively managed patients who were
lass I/II on medical therapy had significantly better HCM-
elated survival (100% at 1 year, 96.3  1.7% at 5 years, and
9.6  3.4% at 10 years) than those who were class III/IV
t the time of the last assessment and who had not
ndergone an invasive intervention (86.9  5.5% at 1 year,
0.7  7.9% at 5 years, and 71.7  10.9% at 10 years, p 
.0001) (Fig. 3).
iscussion
ummary of study findings. In this large cohort of 649
atients with resting obstructive HCM, the majority of
atients experienced an improvement in symptoms and in
he degree of LVOT obstruction, either from increased
edical therapy or from invasive therapy. Overall (but not
CM-related) survival was better in patients who under-
ent an invasive intervention. These outcomes between the
onservative and invasive groups remained consistent in 2
dditional circumstances: 1) when we excluded the DDD
acing group; and 2) when we considered the myectomy
ohort alone in the invasive group (and excluded both the
EA and pacing groups). Patients in the conservative group
ere significantly older and sicker, with almost one-fifth of
atients in the conservatively treated patients having a major
omorbidity. A greater proportion of the conservative group
Figure 2 Comparison of HCM-Related Survival in
Patients With Resting Obstructive HCM
Kaplan-Meier plots of HCM-related survival in patients with HCM and resting
left ventricular outflow tract obstruction managed with either invasive or conser-
vative therapy (p  NS). Abbreviations as in Figure 1.
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(NYHA functional class I/II) conservatively managed pa-
tients had survival similar to patients managed invasively.
Conservative versus invasive therapy. Much of the pub-
lished data since the 1990s have demonstrated that myec-
tomy is associated with excellent long-term survival
(7,8,10,16,17). However, there have been few studies that
have directly compared survival in invasively managed versus
conservatively treated patients. It is well-established that
septal myectomy (7,18), SEA (19), and, to a lesser extent,
DDD pacing (20) improve symptoms. Whether abolition of
the LVOT gradient and the resultant clinical and hemody-
namic improvement translate to enhanced long-term sur-
vival remains controversial. Early studies comparing man-
agement strategies were confounded by high perioperative
mortality that offset the apparent reduction in SCD pro-
vided by myectomy (21) and by inherent differences in the
patient populations referred for surgical versus medical
treatment (22).
A more contemporary comparison of invasively versus
conservatively managed patients was conducted by Ommen
et al. (8). This study compared 289 patients who underwent
myectomy with 228 obstructive patients who were managed
conservatively (and a third cohort of 820 patients with
nonobstructive HCM was also described). Overall survival
and freedom from HCM-related death were greater in the
group treated with myectomy (83% [myectomy] vs. 61%
[conservative] 10-year overall survival; 95% [myectomy] vs.
73% [conservative] 10-year freedom from HCM-related
death). Although this study provides some evidence that
myectomy might permit patients to achieve normal or
near-normal longevity, there were some important differ-
Figure 3 Differences in HCM-Related Survival on the Basis
of Management Strategy and Functional Class
Kaplan-Meier survival curves of HCM-related survival in HCM patients with left
ventricular outflow tract obstruction managed with INV therapy or CONS ther-
apy. Conservatively treated New York Heart Association (NYHA) functional class
I/II patients had similar HCM-related survival to patients treated invasively.
Abbreviations as in Figure 1.ences between this study and our results. First, the invasivelyand conservatively managed patients in the study by Om-
men et al. (8) were treated at different institutions (all
myectomy patients were treated at the Mayo Clinic [Roch-
ester, Minnesota], whereas the nonoperated patients were
managed at 1 of 3 other centers), introducing the possibility
of significant referral bias. Second, our invasive cohort
comprised patients who had any of the 3 types of septal
reduction therapy, whereas the study by Ommen et al. (8)
examined only the outcomes of myectomy patients versus
conservatively managed patients. Third, there is a notable
difference in the survival rates of the conservative groups in
the 2 studies (61% 10-year overall survival in the study by
Ommen et al. (8); 76% in our study), which suggests
intrinsic differences between these 2 cohorts.
Survival analyses comparing invasive versus noninvasive
management. Survival analyses involving patients under-
going an invasive procedure are inherently difficult because,
by definition, all patients must have survived until the date
of intervention. Within our cohort there was only 1 patient
who died while awaiting an intervention, which minimized
the effect of this potential survival bias in our study. In
reality, patients are conservatively treated up until the date
of their invasive procedure and thereafter cross-over to the
invasive cohort. In our study, patients in the invasive group
were managed conservatively for 652 patient-years before
undergoing an invasive intervention. Invasive intervention
was treated as a time-varying covariate in our multivariable
models. Thus, these 652 patient-years were not discounted
and, in fact, were treated in the multivariable models as
survival due to noninvasive therapy.
Clinical and echocardiographic predictors of long-term
survival. The independent determinants of HCM-related
mortality (age 50 years, female sex, septal thickness 20
m, and a resting LVOT gradient 64 mm Hg) identified
in our study further contribute to our understanding of this
condition. We and others have previously shown that
increased age (10,23) and female sex (10,24) were associated
with poorer outcomes in patients with HCM. The degree of
hypertrophy might be regarded as a marker of severity and
of increased risk of SCD in HCM (25). Studies in the past
several years have consistently confirmed worsened survival
in HCM patients with LVOT obstruction, compared with
those without obstruction (6,26,27). However, whether the
actual magnitude of the gradient is associated with increased
mortality has been an unresolved issue. There was no
association between the magnitude of the LVOT gradient
and subsequent clinical deterioration in the study by Maron
et al. (6). In contrast, 2 other large studies have shown a
significant association between the degree of LVOT ob-
struction and overall survival (27,28). The latter study
examined patients with minimally symptomatic obstructive
HCM and also found reduced survival in patients at a
threshold LVOT gradient of 64 mm Hg (28).
Clinical implications. Our study represents the largest
cohort of patients with resting obstructive HCM. The
results of our study have several important clinical implica-
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vatively treated obstructive HCM is much better than
described in other studies (8,21,27). Second, our results
suggest that symptom control and excellent HCM-related
survival can be achieved with medical therapy. In our
conservative cohort, the majority of patients received beta
blockers (80%) and/or disopyramide (60%), which rep-
resent far higher rates of medication use than reported in
other studies (6,8,27). Thus our study extends the findings
of the multicenter study by Sherrid et al. (29), which
provided evidence for meaningful symptom control in pa-
tients taking disopyramide. Third, our results demonstrate
that medically treated class I/II patients with obstructive
HCM have similar overall and HCM-related survival to
patients treated invasively. The subset of conservatively
treated patients who die prematurely are those very symp-
tomatic patients who refuse invasive therapy or who have
serious comorbidities that preclude an invasive intervention.
Thus, despite the excellent reported outcomes for myectomy
and SEA reported by experienced centers, our study lends
support to current recommendations to only refer patients
for invasive septal reduction therapy when they develop
drug-refractory disabling symptoms (5). Fourth, in our large
cohort of 403 invasively treated patients, we found no
difference in 5-year survival between patients undergoing
myectomy or SEA. The duration of follow-up for this
cohort was longer than other previous studies comparing
these 2 treatment strategies (30–34). This intermediate
follow-up information contributes valuable data to the
highly contentious debate surrounding the relative merits of
myectomy versus SEA (35,36). Finally, our study results
confirmed the findings of previous studies that have dem-
onstrated poorer outcomes in patients who underwent
DDD pacing (37).
Study limitations. We acknowledge certain limitations of
the present study. This was a retrospective cohort study. It
is unlikely that a prospective randomized controlled trial will
ever be conducted in patients with obstructive HCM (38).
As with any data from a tertiary care center, there might also
be a referral bias. Clinically stable, asymptomatic, or older
patients might be underrepresented in our cohort. In addi-
tion, given the clinical and technical expertise involved with
both the conservative and invasive management of HCM,
our results might not be generalizable to other centers. Even
though this cohort is the largest dataset in the published
reports of conservative versus invasive treatment in resting
obstructive HCM, we are limited in the number of covari-
ates that can be identified as significant in any 1 model, as
with any study with a relatively small number of endpoints.
Conclusions
Mortality attributable to HCM is similar, regardless of a
conservative versus invasive strategy. However, patients
treated with invasive therapy have an overall survival advan-
tage compared with conservatively treated patients, with thelatter group more likely to die from noncardiac causes.
There was no statistically significant difference in HCM-
related survival between the conservative and invasive
groups even when we reanalyzed the invasive cohort and
1) excluded the DDD pacing subset; and 2) only considered
patients who underwent surgical myectomy. Increasing age,
female sex, increased septal thickness, and a resting LVOT
gradient 64 mm Hg are associated with worsened long-
term survival.
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